FDA Premarket Safety Plan Is Not Cost-Effective – PhRMA
This article was originally published in The Tan Sheet
Executive Summary
Safety requirements outlined in FDA's "Premarketing Risk Assessment" concept paper seem to run counter to cost-effective drug development, which has been stressed by Commissioner Mark McClellan, MD/PhD, PhRMA said during a public workshop on risk management in Washington, D.C. April 9